PrEP has historically faced controversy rooted in social stigma, moral judgments surrounding sexual behavior, and debates over public health funding priorities. Some critics falsely argued that providing preventative medication would encourage reckless sexual practices or increase rates of other sexually transmitted infections, though extensive public health data disproves this claim. Other controversies involve the high initial financial costs of brand-name medications and ensuring equitable access for marginalized communities who experience higher rates of HIV transmission. Over time, growing medical consensus and advocacy have significantly shifted public perception toward recognizing PrEP as a vital breakthrough.
1 votes
Marked as accepted